REGN vs MRNA — Key Metrics

Metric REGN (REGENERON PHARMACEUTICALS INC) MRNA (MODERNA INC)
Price945.53196.79
Market Cap97.81 Billion79.63 Billion
P/E (TTM)20.11-27.8
P/B (Quarterly)2.86515.043
P/S (TTM)5.7931.53
Net Profit Margin (TTM)28.5-110.5
Gross Margin (TTM)85.828.0
ROE (TTM)15.1-37.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

REGENERON PHARMACEUTICALS INC
vs
 
MODERNA INC
 
REGENERON PHARMACEUTICALS INC
vs
 
MODERNA INC
Performance Comparison
AI Model Recommendation
REGN · REGENERON PHARMACEUTICALS INC

Outperform

60
UnderperformOutperform
MRNA · MODERNA INC

Greatly Underperform

-94
UnderperformOutperform
Recommendation Summary

Stock REGN is projected to outperform the market, stock MRNA is projected to greatly underperform the market. Upfront Recommendation: REGN.

Financial Metrics
Prices delayed ~15 min
REGN Metrics MRNA
$945.53 Price $196.79
— Market Capitalization —
5.79 Price to Sales 31.53
6.75 Price to Gross Profit 112.62
14.83 Price to R&D 29.96
4.7 Price to Current Assets 10.84

REGN vs MRNA at a glance

Regeneron Pharmaceuticals INC (REGN) and Moderna INC (MRNA) are both Biotechnology companies in the Healthcare sector. REGN is the larger, at $97.8 billion in market value against $79.6 billion for MRNA, about 1.2 times the size.

On trailing-twelve-month figures, REGN trades at 5.8 times trailing sales and MRNA at 31.5; net profit margins are 28.5% and -110.5%.

The Upfront Investment model currently rates REGN Outperform and MRNA Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.